Rappta
Business Services · Finland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Haartmaninkatu Terkko Health Hub 4, Hels...Website
www.rappta-therapeutics.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Rappta
Rappta Therapeutics is a late preclinical stage biopharmaceutical company focused on developing a first-in-class series of anti-cancer molecular glues that reactivate the tumor suppressor protein phosphatase 2A (PP2A). Their proprietary technology aims to therapeutically reactivate PP2A, which plays a critical role in regulating protein de-phosphorylation and tumor growth. The company has a strong scientific team with expertise in the mechanisms of PP2A inactivation in human cancer. Rappta Therapeutics targets a broad range of human diseases through its innovative approach to cancer treatment.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rappta your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Rappta
Funding: Get notified immidiatlly once Rappta has new funding data
Earning: See what the market has to say on Rappta recently announced quarterly report
Check if Rappta has recently received funding, and reach out quickly before it becomes old news!
Check out if Rappta is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Rappta, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Rappta launches new products
Click to see if Rappta had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Rappta
Find 3 more new buyers
Company Profile Activity
Activity Insights
Rappta is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Rappta is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Rappta.
Rappta financials insights
Gather financial insights about Rappta, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$10.6M
Rappta Tech Stack
A closer look at the technologies used by Rappta
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Executive Move
Executive Moves
Partnership
Partnership, Research & Development, Product Management, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
New Hire
Executive Move
Rappta News & Media
Rappta Therapeutics appoints Sunjeet Sawhney as CEO | MedNous
Finland-based Rappta Therapeutics Oy has appointed Sunjeet Sawhney as chief executive to manage development of its cancer drugs that reactivate PP2A, an enzyme that regulates protein de-phosphorylation. He was most recently global head of oncology at Ipsen SA.Rappta Therapeutics Appoints Sunjeet Sawhney as Chief Executive Officer
HELSINKI and LONDON, Sept. 15, 2021 /PRNewswire/ -- Rappta Therapeutics ("Rappta"), which is focused on developing first-in-class anti-cancer drugs reactivating protein phosphatase 2A (PP2A), announces today the appointment of Sunjeet Sawhney as Chief Executive Officer (CEO) with...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rappta
Sign Up For FreeTo access detailed company insights
Rappta Therapeutics is a late preclinical stage biopharmaceutical company focused on developing a first-in-class series of anti-cancer molecular glues that reactivate the tumor suppressor protein phosphatase 2A (PP2A). Their proprietary technology aims to therapeutically reactivate PP2A, which plays a critical role in regulating protein de-phosphor... Read More
